GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial targets tough digestive cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called PT886 (spevatamig) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check for side effects, and see if the drug shows ear…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Apr 04, 2026 05:20 UTC
-
New drug trial offers hope for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis study is testing a new drug called HLX43 in people with advanced stomach or gastroesophageal cancer that has continued to grow despite standard treatment. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors and help patients live lon…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New pill joins fight against advanced stomach cancer in global trial
Disease control Recruiting nowThis global study is testing whether adding a new oral capsule called UTD2 to standard chemotherapy helps people with advanced stomach or gastroesophageal cancer live longer. It will involve about 778 adults who have not yet received drug treatment for their advanced cancer. The …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC